Nektar Therapeutics (NKTR) Gross Margin (2010 - 2026)

Nektar Therapeutics' Gross Margin history runs 17 years deep, the most recent figure standing at 29.09% for Q1 2026.

• In Q1 2026, Gross Margin rose 9410.0% year-over-year to 29.09%; the TTM figure through Mar 2026 stood at 154.25% (up 10014.0% YoY), while the FY2025 annual figure was 100.0%, up 4272.0% from the prior year.
• Gross Margin was 29.09% for Q1 2026 at Nektar Therapeutics, down from 273.71% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 273.71% in Q4 2025 to a low of 65.01% in Q1 2025.
• Historically, Gross Margin has averaged 73.73% across 5 years, with a median of 70.51% in 2024.
• Biggest YoY gain for Gross Margin was 20320 bps in 2025; the steepest drop was 11323 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 71.7% in 2022, then declined by 3 bps to 69.51% in 2023, then gained by 1 bps to 70.51% in 2024, then surged by 288 bps to 273.71% in 2025, then plunged by 89 bps to 29.09% in 2026.
• The last three Gross Margin figures came in at 29.09% (Q1 2026), 273.71% (Q4 2025), and 100.0% (Q3 2025), per Business Quant data.